| Filed On | Filing |
|---|---|
| 28 Oct 2026 | 6-K |
| 26 Oct 2026 | 6-K |
| 23 Oct 2026 | 6-K |
| 19 Oct 2026 |
Form 4: Woo Ian Ying, Director
Received 13,271 shares by exercise or conversion |
| 13 Oct 2026 | 6-K |
| 21 Sep 2026 |
Form 4: Dennis Phillip Andrew, Chief Medical Officer
Received 23,695 shares by exercise or conversion · Sold 8,209 shares ($5.83K) |
| 18 Sep 2026 | 144 |
| 11 Sep 2026 |
Form 4: Cao Sean Wuxiong, Chief Bus. Development Officer
Sold 107,978 shares ($79.9K) |
| 10 Sep 2026 |
Form 3: Dewhurst Martin William, Director
No securities owned |
| 09 Sep 2026 | 144 |
| 08 Sep 2026 |
Form 4: Cao Sean Wuxiong, Chief Bus. Development Officer
Received 339,372 shares by exercise or conversion |
| 08 Sep 2026 | 6-K |
| 08 Sep 2026 | 6-K |
| 01 Sep 2026 |
Form 4: Xu Cong Claire, EVP, Clinical Development
Received 9,382 shares by exercise or conversion · Sold 3,282 shares ($2.59K) |
| 25 Aug 2026 |
Form 4: Lenz Robert A., Director
Received 17,218 shares by exercise or conversion |
| 20 Aug 2026 | 6-K |
| 20 Aug 2026 | 6-K |
| 17 Aug 2026 | S-8 |
| 24 Jul 2026 | 6-K |
| 17 Jul 2026 | 6-K |
Loading...
